Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTM8B0
|
|||
| Drug Name |
NG-350A
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
PsiOxus Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03852511) First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of PsiOxus Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.